April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
A Specific Expression and Processing for Chromogranin B and Derived Peptides in Human Vitreous, Consecutive to Diabetic Retinopathy
Author Affiliations & Notes
  • D. Gaucher
    Ophthalmology, Hopital Civil de Strasbourg, Strasbourg, France
  • I. Fournier
    Ophthalmology, Hopital Civil de Strasbourg, Strasbourg, France
  • M. Saleh
    Ophthalmology, Hopital Civil de Strasbourg, Strasbourg, France
  • C. Speeg-Schatz
    Ophthalmology, Hopital Civil de Strasbourg, Strasbourg, France
  • T. Bourcier
    Ophthalmology, Hopital Civil de Strasbourg, Strasbourg, France
  • M.-H. Metz
    Inserm, Strasbourg, France
  • Footnotes
    Commercial Relationships  D. Gaucher, None; I. Fournier, None; M. Saleh, None; C. Speeg-Schatz, None; T. Bourcier, None; M.-H. Metz, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4989. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Gaucher, I. Fournier, M. Saleh, C. Speeg-Schatz, T. Bourcier, M.-H. Metz; A Specific Expression and Processing for Chromogranin B and Derived Peptides in Human Vitreous, Consecutive to Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4989.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To ascertain the presence of Chromogranin B (CGB) in human vitreous, and to compare its expression and processing profile in eyes with diabetic retinopathy and control eyes.

Methods: : Vitreous samples were obtained from 5 eyes with proliferative diabetic retinopathy without vitreous hemorrage, and from 8 control eyes with idiopathic macular holes (n=4) or epiretinal membranes (n=4). Soluble CGB concentration was quantified by using Bradford method in the vitreous samples.Isolation of CGB and its derived peptides was obtained by using High-Performance Liquid Chromatography (HPLC). Immunodetection of HPLC fractions containing CGB and CGB derived fragments was obtained after Dot-Blot with specific antibodies. The identification of the sequence of CGB peptides was deduced after automatic Edman sequencing and mass spectrometry analysis.

Results: : CGB was present in all vitreous samples. Soluble proteomic concentration of CGB was significantly higher in eyes with diabetic retinopathy (mean=3,64 µg/µL +/-1.48) than in control eyes (mean= 0,7µg/µL+/-0,46) (p<0.01)CGB derived peptides expressed in diabetic eyes were different from those in controls: apparent molecular mass correspond to large peptides in diabetic eyes (mean=72,8 kDa+/-21.48) versus small peptides in idiopathic macular holes and epiretinal membranes. (mean=21,75kDa+/-6.24) (p<0.01)

Conclusions: : CGB protein was increased in vitreous of patients with diabetic retinopathy and a specific attenuated processing occured. Overexpression, post-translational modifications (glycosylation, glycation) and a decrease of the enzymatic protein might explain these results. Further investigations including proteomic experiments are necessary to understand the role and the different processing of CGB in diabetic retina.

Keywords: vitreous • clinical laboratory testing • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×